Document is current
Any future updates will be listed below
-
Authors
Ketron, Gabriel L
Grun, Felix
Grill, Joshua D
Feldman, Howard H
Rissman, Robert A
Brewer, Gregory J
-
Funding
Funding for this research was provided by:
UC Cures (BRD-16-501530, BRD-16-501530, BRD-16-501530)
Alzheimer’s Association Zenith Award . (#1066394)
- License Information
-
More Information
Article History
Received: 21 September 2024
Accepted: 5 February 2025
First Online: 11 March 2025
Declarations
:
: Consent was waived. Access to participants blood and CSF samples were de-identified. Original participant consent to collect samples was approved by the UC Irvine Institutional Review Board (IRB) []. The trial was conducted in accordance with the International Council for Harmonization guidelines and the ethical principles of the Declaration of Helsinki.
: GLK, FG and GJB report no competing interests. JDG reports research support from NIA, Alzheimer’s Association, BrightFocus Foundation, Eli Lilly, Genentech, Biogen, and Eisai. He received personal income for editorial service to Alzheimer’s & Dementia. HHF reports grant funding from UC Cures BRD-16–501530 with no personal funds received and all payments to the Alzheimer’s Disease Cooperative Study at UC San Diego. HHF also discloses grant funding from Allyx Therapeutics, Biohaven Pharmaceuticals, Vivoryon (Probiodrug), and LuMind Foundation; service agreements for consulting activities with LuMind, Axon Neuroscience, Novo Nordisk, Arrowhead Pharmaceuticals, Roche/Genentech Pharmaceuticals (DMC/DSMB), Tau Consortium (SAB), Janssen Research & Development (DSMB), Biosplice Therapeutics; support for travel from Novo Nordisk, Royal Society of Canada, Translating Research in Elder Care (TREC), Association for Frontotemporal Dementia (AFTD), and Rainwater Charitable Foundation; and a philanthropic donation for the Epstein Family Alzheimer Research Collaboration. For these activities, no personal funds have been received with all payments to UC San Diego. HHF personally receives royalties for patent: Feldman HH (filed November 26, 2008). Detecting and Treating Dementia Serial Number 12/3–2691 U.S. Patent No. PCT/US2007/07008. Washington, DC: U.S. Patent and Trademark Office. RAR has no relevant conflicts. He has research support from the National Institute on Aging, the Alzheimer’s Association and is a consultant for Amydis Inc, Bioivt, Lexeo, Keystone Bio, Allyx, DiamiR, Ionis and PrecisionMed.
